FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
Evidence for efficacy is based on the results from the eNRGy study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1571 results
EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab
New indication concerns a combination of nivolumab and ipilimumab for first-line treatment of patients with dMMR/MSI-H unresectable or metastatic colorectal cancer
Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ
Findings from the COMET study
Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma
Findings from the AQUILA study
EMA Recommends Extension of Indications for Osimertinib
New indication concerns treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status
Findings from the EMBER-3 study
FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer
Evidence for efficacy is based on the results from the HERIZON-BTC-01 study
Lung Adenocarcinoma with Mucinous Histology
Clinicopathologic, genomic, immunophenotypic, transcriptional features, and treatment outcomes
Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult Maternal Cancer
Findings from the IDENTIFY study
Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL
Findings from the FELIX study
EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma
New indication concerns a combination with pemetrexed and platinum for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma
FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation
Evidence for efficacy is based on the results from the AUGMENT-101 study